Keywords
carcinoma medular de tiroides
Calcitonine-negative
calcitonina negativa
Nonsecretory tumor
tumor no secretor
Calcitonin immunostaining
inmunotinción para calcitonina
Poorly differentiated cancer
cancer pobremente diferenciado
How to Cite
Abstract
Objective: medullary thyroid carcinoma (MTC) with normal serum basal calcitonin (calcitonin-negative MTC) is uncommon. The exact mechanism for this paradox is unclear. It has been suggested that the loss of ability to secrete calcitonin is due to tumor cell dedifferentiation and may confer a worse prognosis.
Methods: we describe a 45-year-old woman with a sporadic 4.5-cm well-differentiated MTC, who despite having normal preoperative serum basal calcitonin and poor calcitonin immunostaining in tumor cells, remains in remission 5 years after total thyroidectomy with bilateral central neck dissection. Out of the 20 patients with calcitonin-negative MTC reported to date, we include 16 patients with clinical disease at presentation to determine if they fare worse than their classic MTC counterparts. We try to correlate the extent of calcitonin immunostaining with the degree of tumor differentiation to determine if poor tumor calcitonin immunoreactivity is an indicator of tumor cell dedifferentiation.
Results: Seven and 9 patients with calcitonin-negative MTC had poorly-differentiated and well-differentiated tumors, respectively. Four patients in the former group died from metastatic MTC within 3 years of the diagnosis. The status of the 2 living patients with known follow-up information was one with N1 disease and one in remission. In the well-differentiated group, 2 patients had N1M1 disease and 7 patients were in remission.
According to the number of tumor cells immunoreactive to calcitonin, the 15 patients with known data were classified in 3 groups: 1+ group (only few tumor cells stained weakly for calcitonin), 7 patients; 2+ group (many tumor cells stained focally for calcitonin), 2 patients; and 3+ group (most tumor cells stained strongly for calcitonin), 6 patients. The level of calcitonin immunoreactivity did not correlate with the patient’s clinical status.
Conclusion: the degree of tumor differentiation is a far better predictor of outcome than the extent of calcitonin immunoreactivity and poor tumor calcitonin staining is not necessarily an indicator of tumor cell dedifferentiation.
References
2. De Groot JW, Kema IP, Breukelman H. Biochemical markers in the follow-up of medullary thyroid cancer. Thyroid. 2006;16:1163-1170.
3. Inzerillo AM, Zaidi M, Huang CL. Calcitonin: the other thyroid hormone. Thyroid. 2002;12:791–798.
4. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139-1148.
5. Iglesias P, Vicandi B, Ortega P, Diez JJ. Variante anaplasica del carcinoma medular de tiroides. Med Clin (Barc). 1997;109:276.
6. Diez JJ, Iglesias P. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma. Thyroid. 2004;14:984–985.
7. Niccoli P, Wion-Barbot N, Caron P, Henry JF, de Micco C, Saint Andre JP. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab. 1997;82:338–341.
8. Redding AH, Levine SN, Fowler MR. Normal preoperative calcitonin levels not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses. Thyroid. 2000;10:919–922.
9. Bockhorn M, Frilling A, Rewerk S, Liedke M, Dirsch O, Schmid KW. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma. Thyroid. 2004;14:468–470.
10. Sand M, Gelos M, Sand D, Bechara FG, Bonhag G, Welsing E, Mann B. Serum calcitonin negative medullary thyroid carcinoma. World J Surg Oncol.
2006;4:97-100.
11. Dora JM, Canalli MH, Capp C, Puñales MK, Vieira JG, Maia AL. Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature. Thyroid. 2008;18:895– 899.
12. Giovanella L, Crippa S, Cariani L. Serum calcitonin-negative medullary thyroid carcinoma: role of CgA and CEA as complementary markers. Int J Biol Markers. 2008;23:129–131.
13. Chambon G, Alovisetti C, Idoux-Louche C, Reynaud C, Rodier M, Guedj AM. J Clin Endocrinol Metab. 2011;96:75-81.
14. Alapat DV, Ain KB, Sloan DA, Monaghan KG, Karabakhtsian RG. Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma. Endocrine. 2011;39:148–152.
15. Frank-Raue K, Machens A, Leidig-Bruckner G, Rondot S, Haag C, Schulze E. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma. Thyroid. 2013;23:294–300.
16. Brutsaert EF, Gersten AJ, Tassler AB, Surks MI. J Clin Endocrinol Metab. 2015; 100:337-341.
17. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer. 1984;53:278–285.
18. Trimboli P, Giovanella L. Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature. Clin Chem Lab Med
2015;53:1507-1514.
19. Saad MF, Ordonez NG, Guido JJ, Samaan NA. The prognostic value of calcitonin immunostaining in medullary carcinoma of the thyroid. J Clin Endocrinol Metab. 1984;59:850-856.
20. Kakudo K, Miyauchi A, Katayama S, Watanabe K. Ultrastructural study of poorly differentiated carcinoma of the thyroid. Virchows Arch A. 1987;410:455-460.
Authors must state that they reviewed, validated and approved the manuscript's publication. Moreover, they must sign a model release that should be sent. A copy may be reviewed here